SCHEMBL8918523

SCHEMBL8918523

CNc1ccc2c(c1)Cc1ccccc1-2

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.63
ADRA2A P08913 1/20 0.63
MAOA P21397 1/20 0.63
SLC6A2 P23975 1/20 0.63
HTR2C P28335 1/20 0.63
SLC6A4 P31645 1/20 0.63
HTR2B P41595 1/20 0.63
CYP3A4 P08684 1/20 0.62
SMN1; SMN2 Q16637 4/20 0.58
MAPT P10636 3/20 0.58
HPGD P15428 3/20 0.58
HSD17B10 Q99714 1/20 0.58
RAB9A P51151 7/20 0.56
NPC1 O15118 5/20 0.56
KDM4E B2RXH2 5/20 0.53
LMNA P02545 3/20 0.53
ALDH1A1 P00352 2/20 0.53
TDP1 Q9NUW8 1/20 0.51
MAPK1 P28482 2/20 0.50
CYP2C9 P11712 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20034967 0.92 CYP1A2 (0.54) CYP1A2ADRA2AMAOASLC6A2HTR2C
SCHEMBL19678234 0.90 RAB9A (0.52) CYP1A2ADRA2AMAOASLC6A2HTR2C
SCHEMBL30572826 0.88 CYP1A2 (0.49) CYP1A2ADRA2AMAOASLC6A2HTR2C
SCHEMBL29068503 0.88 CYP1A2 (0.49) CYP1A2ADRA2AMAOASLC6A2HTR2C
SCHEMBL2168131 0.84 CYP1A2 (0.66) CYP1A2ADRA2AMAOASLC6A2HTR2C
SCHEMBL1921953 0.82 CYP1A2 (0.64) CYP1A2ADRA2AMAOASLC6A2HTR2C
SCHEMBL3095573 0.81 CYP1A2 (0.67) CYP1A2ADRA2AMAOASLC6A2HTR2C
SCHEMBL6493994 0.80 CYP1A2 (0.62) CYP1A2ADRA2AMAOASLC6A2HTR2C
SCHEMBL17615520 0.80 CYP1A2 (0.58) CYP1A2ADRA2AMAOASLC6A2HTR2C
SCHEMBL27585673 0.80 RAB9A (0.60) CYP1A2ADRA2AMAOASLC6A2HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115521195-B Preparation method of fluorene formaldehyde compound 上海如鲲新材料股份有限公司 2024-01-26 CN disclosed
EP-3519386-B1 NOVEL PI-CONJUGATED MATERIALS, METHODS FOR PREPARING SAME AND USES THEREOF AS SEMICONDUCTORS DEGBIA MARTIAL (FR) 2023-03-29 EP disclosed
CN-115521195-A Preparation method of fluorene formaldehyde compound 上海如鲲新材料股份有限公司 2022-12-27 CN disclosed
CN-109046463-B Bidentate aza-carbene-manganese catalyst, preparation method and alkylation synthesis application thereof 中山大学 2021-05-04 CN disclosed
US-20170305904-A1 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) 2017-10-26 US disclosed
EP-3232485-A1 BENZIMIDAZO[1,2-A]BENZIMIDAZOLE DERIVATIVES FOR ELECTRONIC APPLICATIONS UDC Ireland Limited (IE) 2017-10-18 EP disclosed
US-9676771-B2 Compounds for inhibiting drug-resistant strains of HIV-1 integrase THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2017-06-13 US disclosed
US-20160083382-A1 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE The United States of American, as represented by the Sec, Dept. of Health and Human Services (US) 2016-03-24 US disclosed
US-8575102-B2 Conjugates having a releasable linkage NEKTAR THERAPEUTICS (US) 2013-11-05 US disclosed
US-20120238750-A1 AROMATIC COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2012-09-20 US disclosed
US-20080227785-A1 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2008-09-18 US disclosed
US-20080227785-A1 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2008-09-18 US disclosed
US-7423148-B2 Small molecule PI 3-kinase inhibitors and methods of their use CHIRON CORPORATION (US) 2008-09-09 US disclosed
US-7423148-B2 Small molecule PI 3-kinase inhibitors and methods of their use CHIRON CORPORATION (US) 2008-09-09 US disclosed
US-7375222-B2 2,4,6-Triamino-1,3,5-triazine derivative ASTELLAS PHARMA INC. (JP) 2008-05-20 US disclosed
US-7375222-B2 2,4,6-Triamino-1,3,5-triazine derivative ASTELLAS PHARMA INC. (JP) 2008-05-20 US disclosed
US-20070270422-A1 Aromatic Compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-11-22 US disclosed
US-20070270422-A1 Aromatic Compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-11-22 US disclosed
WO-2007066784-A2 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 WO disclosed
EP-1757591-A1 CINNAMIDE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238750-A1 AROMATIC COMPOUND CBR1, CBR3, CYP1A1 CYP1A2 79/4885ADRA2A 1128/4885MAOA 624/4885
US-20170305904-A1 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE CCR8, CDK8, CHD8 CYP1A2 2030/4885ADRA2A 2248/4885MAOA 2487/4885
US-20080227785-A1 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE KCNT1, KCNMA1, KCNJ2 CYP1A2 3364/4885ADRA2A 3740/4885MAOA 2945/4885
US-20070270422-A1 Aromatic Compounds COL1A1, COL2A1, COL14A1 CYP1A2 100/4885ADRA2A 637/4885MAOA 317/4885
US-20160083382-A1 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE CCR8, CDK8, CHD8 CYP1A2 2030/4885ADRA2A 2248/4885MAOA 2487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.